Merger & Acquisition Trends in Pharma - Q3 2026
Summary
This report analyzes the merger and acquisition (M&A) activity in Q3 2026 in the Pharma sector.Key Highlights
- In Q3 2026, global pharma M&A value fell 49% quarter over quarter to $51.9 billion in Q3 2026. Deal volume dipped 1.4% to 137 transactions. Oncology emerged as the leading therapeutic area recording 45 deals.
Scope
- This report provides an overview of M&A activity globally in Q3 2026 in the Pharma sector involving biopharmaceutical drug companies.
- It identifies key trends, and the most notable deals announced in Q3 2026 in the Pharma sector.
Reasons to Buy
- Companies that make strategic investments in M&A position themselves for success, while those that fail to adapt risk falling behind.
- This report provides an overview of global M&A trends in the pharma sector from the past quarter, offering insights into the industry landscape and key market movements.
Table of Contents
- About the Analyst
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pharma M&A Analysis in Q3 2026
2.1 Pharma M&A Insights: Deal spotlight
3 Global M&A Trends in Pharma
4 Global Quarterly M&A Trends in Pharma
5 Ownership Type: Private Vs Public (Volume)
6 Ownership Type: Private Vs Public (Value)
7 Global M&A in Pharma by Deal Size Analysis
8 Top M&A Deals in Pharma Q3 2026
9 Regional M&A Comparison in Pharma - Q3 2026
10 Global Cross Border M&A Trends in Pharma
11 Inbound and Outbound M&A Deals in Pharma - Q3 2026
12 Regional M&A Trends in Pharma by Value and Volume
13 M&A Analysis in Pharma by Top 10 Countries
14 M&A Analysis in Pharma by Top 10 Therapy Areas
15 Further Information
15.1 Methodology
16 Contact Us
List of Tables
Table 1: Pharma M&A Insights: Deal Spotlight
Table 2: Top M&A Deals in Pharma Q3 2026
Table 3: Regional M&A Trends in Pharma by Value and Volume
List of Figures
Figure 1: Pharma M&A Analysis in Q3 2026
Figure 2: Global M&A Trends in Pharma
Figure 3: Global Quarterly M&A Trends in Pharma
Figure 4: Ownership Type: Private Vs Public (Volume)
Figure 5: Ownership Type: Private Vs Public (Value)
Figure 6: Global M&A in Pharma by Deal Size Analysis
Figure 7: Regional M&A Comparison in Pharma - Q3 2026
Figure 8: Global Cross Border M&A Trends in Pharma
Figure 9: Inbound and Outbound M&A Deals in Pharma - Q3 2026
Figure 10: Regional M&A Trends in Pharma by Value and Volume
Figure 11: M&A Analysis in Pharma by Top 10 Countries
Figure 12: M&A Analysis in Pharma by Top 10 Therapy Areas
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Vertex Pharmaceuticals
- Crinetics Pharmaceuticals
- Curium US
- Lantheus Holdings
- Eli Lilly
- AtaiBeckley
- The Procter & Gamble
- Thorne Research
- Merida Biosciences
- Supernus Pharmaceuticals
- indivior pharmaceuticals
- Telix Pharmaceuticals
- ITM Isotope Technologies Munich
- Forte Biosciences
- Samsung Biologics
- PolyPeptide Group
- Novartis
- Myricx Pharma
